The incretin class and its metabolic cousins — from single GLP-1 agonists to dual and triple agonists — studied for appetite signaling, glucose regulation, and body composition. Start with a compound, compare the generations, or open a dosing reference.
Start with the fundamentals before comparing compounds.
15 compounds in this research area. Each links to a full profile, dosing chart, and sourcing.
Stabilized GHRH analog
A stabilized GHRH analog that is FDA-approved (as Egrifta) to reduce excess visceral adipose tissue in HIV-associated lipodystrophy — one of the few peptides in this index with an approved human indication.
GLP-1 receptor agonist
A long-acting GLP-1 receptor agonist, FDA-approved for type-2 diabetes and chronic weight management under brand names Ozempic, Wegovy, and Rybelsus. One of the most-studied incretin peptides.
Dual GIP / GLP-1 receptor agonist
A dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (weight management). Trials reported notably large reductions in body weight.
Triple GIP / GLP-1 / glucagon receptor agonist
An investigational 'triple agonist' targeting the GIP, GLP-1, and glucagon receptors. Phase-2 trials reported among the largest weight reductions seen for an incretin agent. Not approved.
Mitochondrial-derived peptide
A mitochondrial-derived peptide studied as a metabolic regulator and exercise-mimetic in preclinical models, and of interest in aging and insulin-sensitivity research.
Modified growth-hormone fragment
A modified fragment of the C-terminus of human growth hormone (residues 176-191) studied for fat metabolism without the full growth-promoting effects of intact GH.
Long-acting amylin analog
A long-acting synthetic analog of the hormone amylin, developed for weight management and most often studied alongside semaglutide in the fixed combination known as CagriSema. It remains investigational.
GLP-1 / glucagon dual receptor agonist
An investigational once-weekly peptide that activates both the GLP-1 and glucagon receptors, studied for obesity and metabolic liver disease (MASH).
GLP-1 / glucagon dual receptor agonist (oxyntomodulin analog)
A once-weekly GLP-1/glucagon dual receptor agonist based on the gut hormone oxyntomodulin. It has been approved in China for weight management and remains investigational in other regions.
Small-molecule NNMT inhibitor (not a peptide)
A small-molecule inhibitor of the enzyme NNMT — not a peptide — studied mainly in cell and animal models for its effects on fat-cell metabolism and its potential to preserve NAD+.
GLP-1 receptor agonist (acylated human GLP-1 analog)
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes) and Saxenda (chronic weight management). It is a once-daily injectable analog of human GLP-1 modified with a fatty-acid chain that extends its duration of action relative to native GLP-1.
Long-acting GLP-1 receptor agonist (GLP-1 analog-IgG4 Fc fusion protein)
Dulaglutide (Trulicity) is an FDA-approved once-weekly GLP-1 receptor agonist for type 2 diabetes and cardiovascular risk reduction. It is a fusion protein linking two modified GLP-1 analog peptides to a human IgG4 Fc fragment, which substantially extends its half-life.
Pro-apoptotic targeting peptide (prohibitin-homing motif fused to a KLAKLAK apoptotic domain)
Adipotide (FTPP) is an experimental targeting peptidomimetic aimed at the vasculature supporting white adipose tissue. In preclinical studies it induced fat loss by triggering apoptosis of the blood vessels feeding fat. It is preclinical/research-only, with notable renal toxicity signals in animal work.
Small-molecule ERR agonist (not a peptide)
SLU-PP-332 is a small-molecule agonist of the estrogen-related receptors investigated as an exercise-mimetic candidate that increases oxidative metabolism and endurance in rodents. Despite being frequently grouped with research peptides, it is not a peptide. Evidence is preclinical with no human data, and it is not approved.
Small-molecule triple monoamine reuptake inhibitor (not a peptide)
Tesofensine is an orally active small-molecule triple monoamine reuptake inhibitor first trialed for neurodegenerative disease and later repurposed for obesity. It is not a peptide. It remains investigational and is not FDA-approved, though it produced notable weight loss in Phase 2 obesity trials.
In-depth, research-framed reading for this category.
Educational summary only. Dosing figures describe how these compounds appear in the research literature and research-community references — they are not a personal treatment plan or a recommendation for human use. For laboratory research use only.
